Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11386819 | 0.98 | NPC1 (0.48) | LMNANPC1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL8376499 | 0.98 | NPC1 (0.48) | LMNANPC1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL9171396 | 0.98 | NPC1 (0.48) | LMNANPC1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL6537081 | 0.98 | NPC1 (0.48) | LMNANPC1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL6588121 | 0.94 | LTA4H (0.44) | LMNANPC1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL9642930 | 0.86 | LMNA (0.41) | LMNASMN1; SMN2TSHRCYP3A4MAPK1 | |
| SCHEMBL11758566 | 0.83 | ALDH1A1 (0.45) | NPC1RAB9ASMN1; SMN2TSHRTP53 | |
| SCHEMBL8955954 | 0.81 | LTA4H (0.44) | LMNANPC1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL14380431 | 0.81 | KCNH2 (0.56) | LMNASMN1; SMN2TSHRMAPK1CHRM2 | |
| SCHEMBL10761888 | 0.81 | LTA4H (0.47) | LMNANPC1RAB9ASMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150890-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | UNIVERSITE DE SHERBROOKE (CA) | 2015-06-04 | — | — | US | claimed |
| US-20120122819-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | SOCPRA - SCIENCES ET GENIE S.E.C. (CA) | 2012-05-17 | — | — | US | claimed |
| EP-2440533-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | Socpra-Sciences Et Génie S.E.C. (CA) | 2012-04-18 | — | — | EP | claimed |
| WO-2010142027-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | SOCPRA - SCIENCES ET GENIE S. E. C. (CA) | 2010-12-16 | — | — | WO | claimed |
| US-20080269258-A1 | Riboswitches, Structure-Based Compound Design with Riboswitches, and Methods and Compositions for Use of and with Riboswitches | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2008-10-30 | — | — | US | claimed |
| US-20080262231-A1 | Processes for Preparing Morphinans and Intermediates Thereof | LIEBEL-FLARSHEIM COMPANY LLC | 2008-10-23 | — | — | US | claimed |
| EP-1828953-A2 | RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH RIBOSWITCHES | Yale University Corporation (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006055351-A2 | STRUCTURE-BASED COMPOUND DESIGN INVOLVING RIBOSWITCHES | YALE UNIVERSITY (US) | 2006-05-26 | — | — | WO | claimed |
| EP-3692017-A1 | SULFUR-CONTAINING COMPOUNDS AND POLYMERS AND THE USE THEREOF IN ELECTROCHEMICAL CELLS | Hydro-Québec (CA) | 2020-08-12 | — | — | EP | disclosed |
| US-9993491-B2 | Guanine riboswitch binding compounds and their use as antibiotics | SOCPRA—SCIENCES ET GÉNIE S.E.C. (CA) | 2018-06-12 | — | — | US | disclosed |
| EP-2440533-B1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | SOCPRA SCIENCES ET GÉNIE S E C (CA) | 2015-09-23 | — | — | EP | disclosed |
| US-20150150890-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | UNIVERSITE DE SHERBROOKE (CA) | 2015-06-04 | — | — | US | disclosed |
| EP-1828953-B1 | Crystalline xpt guanine riboswitch from Bacillus subtilis and structure-based compound identification employing said riboswitch | YALE UNIVERSITY CORP (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120122819-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | SOCPRA - SCIENCES ET GENIE S.E.C. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-20040023984-A1 | Compounds for the treatment of alzheimer's disease | BONNIE DAVIS | 2004-02-05 | — | — | US | disclosed |
| US-6569848-B1 | Analogs of galanthamine; cholinesterase inhibitors | Davis, Bonnie | 2003-05-27 | — | — | US | disclosed |
| US-6319919-B1 | INHIBITING ACETYL CHOLINESTERASE ACTIVITY | Davis, Bonnie | 2001-11-20 | — | — | US | disclosed |
| US-6268358-B1 | Compounds for the treatment of Alzheimer's disease | Davis, Bonnie | 2001-07-31 | — | — | US | disclosed |
| US-6150354-A | TREATING ALZHEIMER'S DISEASE AND RELATED DEMENTIAS BY TREATMENT WITH DERIVATIVES OF GALANTHAMINE BY INHIBITING CHOLINESTERASE ACTIVITY IN A PATIENT | Davis, Bonnie (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0393607-A2 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269258-A1 | Riboswitches, Structure-Based Compound Design with Riboswitches, and Methods and Compositions for Use of and with Riboswitches | RNGTT, SRRT, ATF4 | LMNA 1814/4885NPC1 4435/4885RAB9A 3918/4885 |
| US-20080262231-A1 | Processes for Preparing Morphinans and Intermediates Thereof | NME2, NISCH, NME1 | LMNA 199/4885NPC1 3717/4885RAB9A 1268/4885 |
| US-20150150890-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | GDA, RNMT, GNPDA1 | LMNA 3267/4885NPC1 4063/4885RAB9A 890/4885 |
| US-20040023984-A1 | Compounds for the treatment of alzheimer's disease | GALC, PSEN1, ACHE | LMNA 1543/4885NPC1 641/4885RAB9A 2373/4885 |
| US-20120122819-A1 | GUANINE RIBOSWITCH BINDING COMPOUNDS AND THEIR USE AS ANTIBIOTICS | GDA, RNMT, GNPDA1 | LMNA 3267/4885NPC1 4063/4885RAB9A 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.